All News

38420215_s.jpg

ICYMI: Cancer and TNF inhibitors

Richard Conway, MBBChBAO, PhD

Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.

Read Article
FDA logo

FDA Warning on CAR-T Cell Therapy

Jack Cush, MD

On Nov. 28, 2024, FDA issued a safety alert regarding CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies and that if there is a risk, this only applies to currently approved BCMA-directed and CD19-directed genetically modified autologous CAR T cell immunotherapies. 

Read Article
female with hands

ICYMI: Are Rheumatologists doing Enough for Cervical Cancer?

Eric Dein, MD

Should rheumatologists be counseling patients on cervical cancer prevention and screening?

Read Article
female with hands

Are Rheumatologists doing Enough for Cervical Cancer?

Eric Dein, MD

Should rheumatologists be counseling patients on cervical cancer prevention and screening?

Read Article
38420215_s.jpg

Cancer and TNF inhibitors

Richard Conway, MBBChBAO, PhD

Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.

Read Article
ACR Best

#ACRbest Abstracts – Day 2

Jack Cush, MD

Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media.  Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the SMART Study of MTX, TMP/SMX Prophylaxis, RA-ILD & TNF Inhibitors, cancer research and more. 

Read Article
RheumNow Podcast square

ACR Convergence Preview (11.10.2023)

Jack Cush, MD

Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting. 

Read Article
doctor.study_.decision_0.jpg

Oral Surveillance Study Alters Practice at VA

Jack Cush, MD

Safety risks found in a postmarketing trial with the Janus-associated kinase (JAK) inhibitor tofacitinib (Xeljanz) appear to have influenced prescribing patterns across the class for rheumatoid arthritis (RA) patients in the Veterans Affairs (VA) health system, researchers found.

Read Article
Are Rheumatologists doing Enough for Cervical Cancer? Should rheums be counseling patients on cervical cancer prevention and screening? The data from Abstract #1479 at #ACR23 suggests this should be an important conversation with our lupus patients. https://t.co/VFobM0T3u7 https://t.co/L45N3tsTdN

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR23 Abstr#2575 Do guidelines work? Data from UK cohort (N=290) re: utility of the International Guideline for IIM-assoc cancer screening detected 17 cases; most in high risk group & none in low risk. Need larger size, cases, screening timepoint & economic analysis @RheumNow https://t.co/G2bmmQbSox
Md Yuzaiful Md Yusof  ( View Tweet)
Lung cancer in RA. @NamrataRheum et al. 26,625 RA HR for lung cancer for b/tsDMARDs vs csDMARDS 1.07 (0.91-1.26) Abstr#0453 #ACR23 @RheumNow https://t.co/NLNtyYoaoH https://t.co/tRpt62n62X
Richard Conway  ( View Tweet)
Age does NOT affect the chance of getting irAE or the severity when using check point inhibitors to treat cancer. Data from #CANRIO database in #Canada #ACR 23 @ACRheum @RheumNow #1063 https://t.co/bqbiXzdAqr
Janet Pope  ( View Tweet)
Obs study, bDMARDs & malignancy TNFi w/lower risk than ABA/RTX/IL6i & numerically lower than JAKs I'm a little skeptical... KM curves diverged w/~45 days, seems implausible? Agree w/first author, possible channeling bias @RheumNow #ACR23 Abstr 1678 https://t.co/1uL3j6kTSj
Mike Putman EBRheum ( View Tweet)
Large observational study of TNF use among patients with RA & cancer Overall encouraging, no negative impact on survival I'm kind of a TNF-truther on this; I don't think they cause ANY increased risk of malignancy @RheumNow #ACR23 Abstr 1675 https://t.co/KRVlIFxhl8
Mike Putman EBRheum ( View Tweet)
2 RA cohorts w/Breast Cancer 17% TNFi within 1yr after surgery No diff in overall survival at 5 yr w/ TNFi or csDMARD Trend towards better BC specific survival w/ TNFi vs. csDMARD only Worst survival for GC>7.5mg/day Only 2 yrs follow up @RheumNow #ACR23 ABST1675 https://t.co/ekKlJ2dP5i
Aurelie Najm  ( View Tweet)
1-Can we prevent RA ? Vagotomy? 2-CV events in auto immune rheumatic disease pregnancies. 3-CVS vasculitis , challenges and role of Brain biopsy And others…….. https://t.co/BX8bDSX1M3 @RheumNow , daily recap #ACR23

Nouf Al hemmadi  ( View Tweet)

No more underpowered long-term safety studies We need a "SELECT-SURVEILLANCE" study to replicate ORAL-SURVEILLANCE & tell us if UPA has the same MACE/cancer risk as TOFA Minus that, I plan to go 100% TOFA when it becomes generic in 2026 @RheumNow #ACR23 Abstr1326 https://t.co/LyQ1Q8qReO
Mike Putman EBRheum ( View Tweet)
Yet another (mostly) reassuring report about lymphoma and DMARDS The skin cancer signal in the CIRT trial was weird; would be worth looking into that in observational studies as well @NamrataRheum #ACR23 Abst0438 @RheumNow https://t.co/Beg8UUe2mn
Mike Putman EBRheum ( View Tweet)
Nice VA study evaluating risk of lung cancer w/respect to RA treatment strategies Take home? No association. Aside from the (small risk) w/JAKi's, I think malignancy risks have been mostly overblown @NamrataRheum @RheumNow ABST0453 #ACR23 https://t.co/lDz0nV1KHt
Mike Putman EBRheum ( View Tweet)
Biologics, #RA and Risk of skin CA (NMSC) is complex. - RA alone is a risk for NMSC 49K study of ABA & NMSC ; - In RCTs, risk same w/ ABA & PBO - Registries & Claims data: equal w/ ABA, csDMARDs. b/tsDMARDs - Pooled obs data shows slight ABA risk https://t.co/tp6F0cJWug https://t.co/u6UdAUZqoc

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×